by Site Strategics | Feb 9, 2023 | News
MIRAVISTA DIAGNOSTICS WILL BE AT THIS EVENT ATS 2024 showcases the latest advances and discoveries in respiratory science, patient care and global respiratory health. See us at booth 1431. (https://conference.thoracic.org/)
by Site Strategics | Oct 14, 2021 | News
The second US based multicenter study found high concordance with the MiraVista LFA and EIA and reported higher sensitivity with the EIA. Read more about the US LFA Multicenter Study.
by Site Strategics | Oct 14, 2021 | News
Several studies have recently been published, evaluated the MVista® CE marked Histoplasma urine antigen lateral flow immunoassay. The first study was conducted in Columbia in partnership with the CDC and reported high sensitivity with the MVD LFA. Read more about the...
by Site Strategics | Mar 3, 2021 | News
In compliance with NIAID/NIH guidelines research at MiraVista Diagnostics utilizing synthetic or recombinant DNA is annually reviewed by the MiraVista Institutional Biosafety Committee (IBC). The IBC is made up of internal and external subject matter experts to ensure...
by Site Strategics | Nov 30, 2020 | News
In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our referral testing customers. Beginning March 1, 2021 MiraVista Diagnostics will transition to an improved MVista® Histoplasma Antigen Quantitative...
by Site Strategics | May 14, 2020 | News
Are You Underdiagnosing Coccidioidomycosis? Capture Additional Cases with Combined Antigen and Antibody Testing. Dear Colleagues, The prevailing method for diagnosis of coccidioidomycosis is serum antibody testing by immunodiffusion (ID) with a sensitivity of 84.2%...